Premium
Preparation, biodistribution, and micropet imaging of 45 Ti‐transferrin
Author(s) -
Vävere A. L.,
Jones L. A.,
Mccarthy T. J.,
Rowland D. J.,
Welch M. J.
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.25804401279
Subject(s) - transferrin , biodistribution , chemistry , titanium , transferrin receptor , in vivo , in vitro , radiochemistry , metal , biophysics , nuclear chemistry , biochemistry , organic chemistry , microbiology and biotechnology , biology
Several titanium complexes are currently being investigated for their ability to exhibit antitumor activity both in vitro and in vivo (1). Sun et al. recently showed the first specific Ti(IV)‐protein complex through binding experiments with transferrin (2). This suggests that transferrin could be the mode of transport for titanium anticancer drugs since tumor cells show high levels of transferrin receptors on the cell surface (3). Transferrin has a molecular weight of 80 kDa and is only 30% saturated with iron, leaving available binding sites for other metal ions (4). Titanium‐45 has a half‐life of 3.09 hours and a positron branching ratio of 85% with an E β+max of 1.04 MeV. The work of Ishiwata et al. investigated 45 Ti as a potential metal for labeling pharmaceuticals for PET imaging (5). In the current study, the biodistribution of 45 Ti‐transferrin was examined to investigate the mode of transport of titanium compounds to tumors.